Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals announced on Monday that it will acquire the genetic testing business and most assets of 23andMe ...

Me is teetering on the edge of bankruptcy and actively seeking a buyer. That buyer, unless explicitly restricted, could gain ...

Before, we told you to delete your data because 23andMe was about to be sold. Now, a buyer has been announced, and they’re ...

The pharmaceutical giant plans to continue offering 23andMe’s DNA testing service and pledged to adopt its privacy practices to protect customer data.

A crucial step in handling the sale of genetic data from over 15 million 23andMe customers now rests largely in the hands of ...

A key decision by the bankruptcy judge could help with protecting consumer data, write Diane Lourdes Dick and Anya Prince.

Drugmaker acquires DNA testing firm and gains access to massive genetic database ● Consumer genome services to continue; ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

Regeneron Pharmaceuticals has bought the genetic testing company 23andMe, a company once valued at $6bn, for $256m through a ...

Me's sale to Regeneron transfers genetic data for drug development, raising privacy issues and concerns over consumer control ...